Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 2/20 | 0.55 |
| ▸ | SKP1 | P63208 | 2/20 | 0.55 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.55 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21521592 | 1.00 | CKS1B (0.55) | CKS1BSKP1SKP2GPR119HPGD | |
| SCHEMBL31410460 | 0.90 | GPR119 (0.47) | CKS1BSKP1SKP2GPR119HPGD | |
| SCHEMBL31410466 | 0.90 | GPR119 (0.47) | CKS1BSKP1SKP2GPR119HPGD | |
| SCHEMBL30328476 | 0.89 | GPR119 (0.49) | CKS1BSKP1SKP2GPR119HPGD | |
| SCHEMBL31466503 | 0.87 | CKS1B (0.46) | CKS1BSKP1SKP2GPR119HPGD | |
| SCHEMBL30328958 | 0.86 | CYP11B2 (0.46) | CKS1BSKP1SKP2GPR119SLC6A9 | |
| SCHEMBL30329263 | 0.85 | CYP11B2 (0.48) | CKS1BSKP1SKP2GPR119HPGD | |
| SCHEMBL30409946 | 0.84 | RET (0.43) | CKS1BSKP1SKP2GPR119SLC6A9 | |
| SCHEMBL30898352 | 0.84 | RET (0.43) | CKS1BSKP1SKP2GPR119SLC6A9 | |
| SCHEMBL14614610 | 0.84 | CKS1B (0.59) | CKS1BSKP1SKP2GPR119HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025045246-A1 | PARP7 INHIBITOR AND USE THEREOF | 重庆华森英诺生物科技有限公司 | 2025-03-06 | — | — | WO | disclosed |
| US-20250034120-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS, INC. | 2025-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034120-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | CKS1B 376/4885SKP1 1295/4885SKP2 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.